Funded Project Details - FY2021
|Title:|| Translational development of FDA-approved COX and LOX inhibitors to treat spinal cord injury-induced neuropathic pain.|
|Congressional District Code:
||Biomedical Laboratory R&D
|| January 2018 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Project Summary/Abstract: Spinal cord injury (SCI) produces a permanent loss of function below the level of damage. In addition, more than 80% of SCI patients report the development of horribly debilitating neuropathic pain (NP) that further robs the individual of life quality. NP can be an almost constant pathological companion for these individuals and represents a significant cause of suicide in the chronic SCI population. Unfortunately, there are few therapeutic options available to treat NP...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.